Implantable cardioverter defibrillators (ICDs) are widely used and known to decrease mortality in patients at risk for sudden cardiac arrest and high-risk cardiac disease.\(^1\)\(^-\)\(^3\) However, at the same time, ICD shocks can have adverse effects on quality of life and the psychological state of patients. Studies have detected that the physical and mental health state of patients deteriorates with the delivery of ICD shocks.\(^4\)\(^-\)\(^6\) As the number of shocks increases, patients are hospitalized for longer periods, which also adversely affects healthcare expenses. In addition, frequent shocks may shorten the battery life of the device. It has been reported that in 2 years post implantation, appropriate ICD shocks were delivered to only 50% to 70% of patients with an ICD implanted to manage ventricular tachycardia/fibrillation (VT/VF).\(^7\)\(^-\)\(^10\) Inappropriate shocks have been seen in 15% to 25% of patients.\(^11\)\(^,\)\(^12\) Predictors of ICD shock have been thoroughly investigated. The potential usefulness of parameters such as ejection fraction (EF), renal dysfunction, age, and atrial fibrillation (AF) has been demonstrated.\(^13\) If we can identify the pa-
patients at risk for inappropriate shock after ICD implantation, then the ability to prevent these shocks may increase.

The Tei index is not affected by the geometric configuration of ventricle as delineated by Doppler echocardiography, and it is used in the assessment of both systolic and diastolic functions of the ventricle. The simplicity and reproducibility of this technique offer an advantage to the physician. It has a prognostic value in a wide spectrum of cardiac diseases, from myocardial infarction to heart failure. This study was an investigation of the use of the Tei index in patients who received ICD shocks.

Methods

Patient Population
A retrospective analysis was conducted of the baseline characteristics of patients who received an ICD between 2013 and 2015 and 2 years of follow-up data. ICD devices were implanted in a total of 250 patients with the diagnosis chronic heart failure (CHF), with or without a documented heart attack, in compliance with the current guidelines. Baseline physical electrocardiographic and echocardiographic examination details, laboratory results, and risk factors were retrieved from patient files and recorded. Patients who did not complete 2 years of follow-up for any reason (excluding those who died after receiving ICD shock therapy with the indication of arrhythmia) were not included in the study. Furthermore, patients were excluded from the study if the estimated Tei indices were not reliable; if AF, aortic stenosis, or atrioventricular block was present; or if they had a pacemaker with a basal battery rhythm. The patients were grouped according to those who had and had not received shock therapy, and intergroup characteristics were analyzed. The study protocol was approved by the Ethics Committee of Mersin University.

The Devices and Programs Used
The ICD was implanted from the left pectoral region in all cases. During and after the procedure, device threshold and sensing measurements were made. The devices used were all manufactured by Biotronik SE & Co. KG (Berlin, Germany) and standard defibrillator programs were used. If the heart rate is between 130 and 161 bpm, then the device records the cardiac event without delivering any treatment. In Zone 2, a ventricular arrhythmia greater than 162 bpm is perceived as VT and antitachycardic pacing of 2 bursts and 2 ramps is delivered. In the event of persistent arrhythmia, the device delivers defibrillator shocks. However in Zone 3, if a ventricular arrhythmia is greater than 210 bpm, the device delivers a shock as the initial treatment. Algorithms to distinguish between supraventricular tachycardia and VT are activated to prevent delivery of inappropriate shocks.

Calculation of the Tei Index
The Tei index is measured using ejection time, and the isovolumetric contraction and relaxation times, determined based on Doppler echocardiographic values (Fig. 1). These time periods may be calculated from recordings obtained from apical 5-chamber echocardiographic views with the sample volume placed just behind the aortic valve, that is, over the left ventricular outflow tract.

Follow-up
All of the devices were checked at an average interval of 3 months and the data obtained were recorded. Appropriate and inappropriate ICD shocks were determined and recorded. ICD shocks not delivered for VT or VF were interpreted as inappropriate shocks. Patients who had missing data for a period of more than 6 months were considered lost to follow-up.

Statistical Analysis
The Shapiro-Wilks test was used when the normality test of the numerical variables was n<50, and the Kolmogorov-Smirnov test was used when the n>50. In comparisons of 2 independent groups, when the data were normally distributed, a parametric independent samples t-test was used. In comparisons of categorical variables, which were tabulated in 2x2 tables, Pearson’s chi-square test was used. The statistical analyses were performed using the R 3.3.2 program (The

Figure 1. Calculation of Tei index.
R Foundation for Statistical Computing, Vienna, Austria), and the level of significance was a p value of 0.05.

Results

The comparison of the baseline demographic and clinical characteristics of patients who did and did not receive ICD shocks in the 2-year period after ICD implantation is provided in Table 1. In this study population with heart failure, among the patients who did receive shock therapy (appropriate or inappropriate), the mean age of the patients was older (p<0.001), and the incidence of hypertension was greater (p=0.002), as well as the number of smoking pack-years (p<0.001) compared with the patients who did not receive a shock.

In all, 28.9% of the CHF patients who underwent ICD implantation for primary prophylaxis received shock therapy, while 71.1% of the patients for whom ICD implantation was for secondary prophylaxis received appropriate or inappropriate shocks (p<0.001).

The EF index was lower and the Tei index was higher in the

| Table 1. Comparison of basic demographic and clinical characteristics of patients who did and did not receive an ICD shock within 2 years after ICD implantation |
|---------------------------------------------------------------|
| **No ICD shock (n=205)** | **ICD shock delivered (n=45)** | **p** |
| Age (years) | 58.44±9.1 | 67.11±9.75 | <0.001 |
| Sex, n (%) | | | |
| Female | 68 (33.2) | 13 (28.9) | 0.578 |
| Male | 137 (66.8) | 32 (71.1) |  |
| Hypertension, n (%) | | | |
| Yes | 120 (58.5) | 15 (33.3) | 0.002 |
| No | 85 (41.5) | 30 (66.7) |  |
| Diabetes mellitus, n (%) | | | |
| No | 154 (75.1) | 37 (82.2) | 0.310 |
| Yes | 51 (24.9) | 8 (17.8) |  |
| Smoking, n (%) | | | |
| No | 96 (46.8) | 6 (13.3) | <0.001 |
| Yes | 109 (53.2) | 39 (86.7) |  |
| Ischemic etiology, n (%) | | | |
| No | 51 (24.9) | 8 (17.8) | 0.310 |
| Yes | 154 (75.1) | 37 (82.2) |  |
| Primary prophylaxis, n (%) | | | |
| No | 59 (28.8) | 32 (71.1) | <0.001 |
| Yes | 146 (71.2) | 13 (28.9) |  |
| Secondary prophylaxis, n (%) | | | |
| No | 146 (71.2) | 13 (28.9) | <0.001 |
| Yes | 59 (28.8) | 32 (71.1) |  |
| Hyperlipidemia, n (%) | | | |
| No | 75 (36.6) | 16 (35.6) | 0.897 |
| Yes | 130 (63.4) | 29 (64.4) |  |
| Stroke, n (%) | | | |
| No | 124 (60.5) | 23 (51.1) | 0.247 |
| Yes | 81 (39.5) | 22 (48.9) |  |
| Body mass index* | 27.05±2.43 | 26.5±2.7 | 0.190 |
| Systolic blood pressure*, mmHg | 125.37±7.22 | 127.33±7.80 | 0.104 |
| Diastolic blood pressure*, mmHg | 74.05±6.24 | 75.44±5.92 | 0.172 |
| Pulse rate*, bpm | 68.15±6.04 | 67.31±7.17 | 0.416 |
| Ejection fraction*, % | 32.32±4.68 | 27.09±4.82 | <0.001 |
| Glomerular filtration rate*, mL/min/1.73m² | 76.75±13.98 | 54.87±11.80 | <0.001 |
| Tei index* | 0.56±0.10 | 0.70±0.10 | <0.001 |

Chi-square test was used to compare categorical variables; Student’s t-test was used for the comparison of numerical variables; *Numerical data are reported as mean±SD; ICD: Implantable cardioverter defibrillator.
group who received shock therapy within 2 years following ICD implantation relative to those who didn’t receive shock therapy (p<0.001). The mean estimated glomerular filtration rate (eGFR) was also higher in the group that received shock therapy (p<0.001).

Among the entire study population (n=250), a weak but significant negative correlation was observed between the Tei index value and age of the patients (p<0.001) (Table 2). The Tei index value increased in parallel with the age of the patients, while the EF and eGFR scores decreased as age increased (p<0.001 for both).

A strong negative correlation was found between eGFR value and the Tei index: the Tei index value increased as the eGFR value decreased (p<0.001).

**Discussion**

This study was an investigation of echocardiographic findings, which may predict ICD shocks in patients with implanted ICD devices. In our study population, a significantly higher Tei index value was detected in CHF patients who received either appropriate or inappropriate ICD shocks within 2 years after ICD implantation compared with those who did not.

A correlation between ICD shocks and mortality has been reported, regardless of whether the ICD shocks are appropriate or inappropriate. The risk increases slightly in patients receiving appropriate ICD shocks. In addition, after 5 inappropriate shocks, each ICD shock has been associated with a 3.7 times increase in mortality. Myocardial damage has been demonstrated in patients who received ICD shocks.

However it is still controversial whether or not ICD shocks are a cause or an outcome of increased risk of mortality. According to some opinions, deterioration of left ventricular function during the natural course of heart failure increases the frequency of arrhythmic episodes and thus, ICD shocks. AF, which is the most commonly seen arrhythmia in heart failure, is the most frequent cause of inappropriate ICD shocks. The occurrence of AF is an independent marker of mortality in heart failure and a greater number of shocks increases mortality.

While an ICD can provide benefits, ICD shocks can also adversely affect the physical and mental health of recipients. Multiple ICD shocks often seriously frighten patients and some even have concerns that the device may kill them. Fear sometimes leads some of these patients to refrain from performing daily activities.

The Tei index is the sum of both isovolumetric times divided by the ejection time. In patients with impaired cardiac function, the isovolumetric contraction time and the isovolumetric relaxation time are prolonged, while the ejection time is shortened. Therefore, the Tei index value of cardiac patients is greater than that of healthy individuals. The prognostic value of the Tei index has been demonstrated in patients who experienced myocardial infarction, dilated cardiomyopathy, and the general population.

One study has reported a cardiovascular mortality rate nearly 13 times higher in cardiac failure patients with a Tei index value greater than 0.67.

It is reasonable to assume that the decline of cardiac sufficiency increases the frequency of arrhythmia and increases mortality in patients who receive appropriate shock therapy. Our results indicate that a greater Tei index value, which may be a criterion of a clinically poor prognosis, is also associated with increased frequency of ICD shocks.

In our study, ICD shocks were more frequently observed in patients who had an ICD implanted as secondary prophylaxis. This finding has been reported in various studies.

We also detected a correlation between smoking and ICD shocks. Sanchez et al. also observed a significant correlation between smoking and ICD shocks.

In conclusion, this research revealed a correlation between the Tei index and ICD shocks. The ability to predict ICD shocks may allow for preventive measures to be taken. The Tei index is easily standardized and measurable echocardiographic parameter that may be a useful tool. Prospective, randomized studies could provide additional, valuable results.

**Disclosures**

**Ethics Committee Approval:** The study was approved by the Local Ethics Committee.

**Peer-review:** Externally peer-reviewed.

**Conflict of Interest:** None declared.

**References**

1. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933–40.

2. Antiarrhythmics versus Implantable Defibrillators (AVID) Inves-
tigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576–83.

3. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al.; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–83.

4. Sears SF Jr, Todaro JF, Lewis TS, Sotile W, Conti JB. Examining the psychosocial impact of implantable cardioverter defibrillators: a literature review. Clin Cardiol 1999;22:481–9.

5. Schulz SM, Massa C, Grzbiela A, Dengler W, Wiedemann G, Pauli P. Implantable cardioverter-defibrillator shocks are prospective predictors of anxiety. Heart Lung 2013;42:105–11.

6. Irvine J, Dorian P, Baker B, O’Brien BJ, Roberts R, Gent M, et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J 2002;144:282–9.

7. Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS, Cook JR, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002;105:589–94.

8. Mark DB, Anstrom KJ, Sun JL, Clapp-Channing NE, Tsiatis AA, et al.; Sudden Cardiac Death in Heart Failure Trial Investigators. Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med 2008;359:999–1008.

9. Noyes K, Corona E, Veazie P, Dick AW, Zhao H, Moss AJ. Examination of the effect of implantable cardioverter-defibrillators on health-related quality of life: based on results from the Multicenter Automatic Defibrillator Trial-II. Am J Cardiovasc Drugs 2009;9:393–400.

10. Block M, Breithardt G. Long term follow-up and clinical results of implantable cardioverter – defibrillators. Cardiac Electrophysiology -From Cell to Bedside. Philadelphia: W.B. Saunders;1995;1412–25.

11. Rosenqvist M, Beyer T, Minten J, Lindemans F. Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. European 7219 Jewel ICD investigators. Circulation 1998;98:663–70.

12. Nunain SO, Roelke M, Trouton T, Osswald S, Kim YH, Sosa-Suarez G, et al. Limitations and late complications of third-generation automatic cardioverter-defibrillators. Circulation 1995;91:2204–13.

13. van Rees JB, Borleffs CJ, de Bie MK, Stijnen T, van Erven L, Bax JJ, et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol 2011;57:556–62.

14. Tei C. New non-invasive index for combined systolic and diastolic ventricular function. J Cardiol 1995;26:135–6.

15. Proietti R, Labos C, Davis M, Thanassoulis G, Santangeli P, Russo V, et al. A systematic review and meta-analysis of the association between implantable cardioverter-defibrillator shocks and long-term mortality. Can J Cardiol 2015;31:270–7.

16. Toh N, Nishii N, Nakamura K, Tada T, Oe H, Nagase S, et al. Cardiac dysfunction and prolonged hemodynamic deterioration after implantable cardioverter-defibrillator shock in patients with systolic heart failure. Circ Arrhythm Electrophysiol 2012;5:898–905.

17. Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P, et al.; MADIT II Investigators. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008;51:1357–65.

18. Dougherty CM. Psychological reactions and family adjustment in shock versus no shock groups after implantation of internal cardioverter defibrillator. Heart Lung 1995;24:281–91.

19. Sears SE Jr, Conti JB. Understanding implantable cardioverter de-fibrillator shocks and storms: medical and psychosocial considerations for research and clinical care. Clin Cardiol 2003;26:107–11.

20. Anavekar NS, Mirza A, Skali H, Plappert T, St John Sutton M, Pfeffer MA, et al.; Survival and Ventricular Enlargement (SAVE) Investigators. Risk assessment in patients with depressed left ventricular function after myocardial infarction using the myocardial performance index- Survival and Ventricular Enlargement (SAVE) experience. J Am Soc Echocardiogr 2006;19:28–33.

21. Arnlov J, Ingelsson E, Risérus U, Andrén B, Lind L. Myocardial performance index, a Doppler-derived index of global left ventricular function, predicts congestive heart failure in elderly men. Eur Heart J 2004;25:2220–5.

22. Dujardin KS, Tei C, Yeo TC, Hodge DO, Rossi A, Seward JB. Prognostic value of a Doppler index combining systolic and diastolic performance in idiopathic-dilated cardiomyopathy. Am J Cardiol 1998;82:1071–6.

23. Olson JM, Samad BA, Alam M. Myocardial Performance Index Determined by Tissue Doppler Imaging in Patients With Systolic Heart Failure Predicts Poor Long-Term Prognosis: An Observational Cohort Study. J Card Fail 2016;22:611–7.

24. van Welsenes GH, van Rees JB, Borleffs CJ, Canneugieter SC, Bax JJ, van Erven L, et al. Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients. Europace 2011;13:389–94.

25. Sánchez JM, Greenberg SL, Chen J, Gleva MJ, Lindsay BD, Smith TW, et al. Smokers are at markedly increased risk of appropriate defibrillator shocks in a primary prevention population. Heart Rhythm 2006;3:443–9.